Open label oncolytic virus treatment of refractory cancer under the EU hospital exemption, article 28 of Regulation 1394/2007/EC.
Phase of Trial: Clinical Phase Unknown
Latest Information Update: 02 Aug 2013
At a glance
- Drugs ONCOS 102 (Primary) ; Antineoplastics; Oncolytic viruses
- Indications Solid tumours
- Focus Biomarker; Therapeutic Use
- Acronyms ATAP
- 02 Aug 2013 Status changed to suspended. The programme is on hold and not recruiting patients, due to the initiation of clinical trials.
- 07 May 2011 New trial record